Back

New Treatment Paradigms: Alfapump

Ascites is an early and common complication of decompensated cirrhosis. The FDA approval of the Alfapump system presents a new option for treating ascites, providing a different option to improve quality of life for patients with cirrhosis. In this interview, Drs. Jasmohan Baja and Catherine Lucero discuss the optimal criteria for patient selection, perioperative and postoperative complications, the impact of quality of life and long-term outcomes for incorporating this new option into clinical practice.

Credit & MOC Details

Credit information is provided by the course provider. We recommend confirming credit eligibility with the provider or your licensing board before starting the activity.

Credit types

AMA PRA Category 1 Credit™Up to 0.25 credits

MOC types

No MOC

FDA REMS

No

Qualifies for MIPS

No

Pricing

Paid · fee on provider site

See fees on liverlearning.aasld.org

Listed by the provider

  • Online course / module
  • Credit · Up to 0.25 credits
  • Paid · fee on provider site
  • Released
    Sep 25, 2025
  • Last day to claim credit
    Sep 26, 2027 12 months left